pdf   xlsx method abbreviations

lung cancer : non small cell (NSCLC), ... versus bevacizumab based treatment, meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.92 [0.70, 1.21]< 10%1 study (1/-)73.1 %NAnot evaluable crucial-
progression or deaths (PFS) 0.71 [0.58, 0.86]< 10%1 study (1/-)100.0 %NAnot evaluable important-

safety endpoints 00

AE (any grade) 3.87 [2.10, 7.15]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
AE (grade 3-4) 1.74 [1.29, 2.35]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
AE leading to death (grade 5) 1.62 [0.52, 4.99]< 10%1 study (1/-)20.2 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.